恶性疟原虫血期疫苗BK-SE36联合CpG-ODN(K3)首次人体随机试验及随访研究
在日本大阪大学医院对26名疟疾未暴露健康日本男性成人开展研究者发起的随机单盲安慰剂对照剂量递增1a期试验,评估BK-SE36联合CpG-ODN(K3)的安全性及免疫原性,并随访1年。结果显示疫苗耐受良好,未出现临床自身免疫病证据,全程剂量组抗体滴度显著高于半剂量组,抗体应答持续12个月。
要点
- BK-SE36/CpG耐受良好,接种部位反应与BK-SE36相似
- 全程剂量组第二次接种后21天抗体滴度显著高于半剂量组(p=0.002)
- 抗体滴度在12个月随访期间持续高于基线
核心结论
- BK-SE36/CpG安全性可接受,CpG-ODN(K3)显著增强疟疾未暴露日本成人的免疫原性。
研究设计与样本
- 研究者发起的随机单盲安慰剂对照剂量递增1a期试验,在大阪大学医院开展,纳入26名健康疟疾未暴露日本男性成人。
- 试验分两阶段:半剂量组BK-SE36/CpG 7例、对照3例;全程剂量组BK-SE36/CpG 11例、对照5例。
- 两组均间隔21天肌肉注射两次,半剂量为0.5 ml含50 µg SE36+500 µg铝+500 µg K3,全程剂量为1.0 ml含100 µg SE36+1000 µg铝+1000 µg K3。
- 随访1年监测自身免疫标志物变化及疫苗诱导抗体应答。
主要发现
- BK-SE36/CpG耐受良好,接种部位反应与BK-SE36相似,试验及随访期间无受试者出现临床自身免疫病证据。
- 全程剂量组第二次接种后21天抗体滴度显著高于半剂量组(Student t检验,p=0.002)。
- 抗体滴度在12个月随访期间持续高于基线值。
- 疫苗诱导抗体主要为IgG1和IgM,识别SE36中部多聚丝氨酸区域附近的表位。
关键数值与推荐
- 全程剂量组第二次接种后21天抗体滴度显著高于半剂量组(p=0.002)。
- 半剂量配方:0.5 ml含50 µg SE36+500 µg铝+500 µg K3。
- 全程剂量配方:1.0 ml含100 µg SE36+1000 µg铝+1000 µg K3。
- 两次肌肉注射间隔21天。
临床怎么用
- 提示BK-SE36/CpG在疟疾未暴露成人中安全性可接受且免疫原性增强,支持后续在疟疾流行区进一步评估。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BK-SE36 is blood-stage malaria vaccine candidate that is undergoing clinical trials. Here, the safety and immunogenicity of BK-SE36 with a novel adjuvant, CpG-ODN(K3) (thus, BK-SE36/CpG) was assessed in a phase 1a trial in Japan. METHODS: An investigator-initiated, randomised, single-blind, placebo-controlled, dose-escalation study was conducted at Osaka University Hospital with 26 healthy malaria naïve Japanese male adults. The trial was conducted in two stages: Stage/Group 1, half-dose (n = 7 for BK-SE36/CpG and n = 3 for control) and Stage/Group 2, full-dose (n = 11 for BK-SE36/CpG and n = 5 for control). There were two intramuscular vaccinations 21 days apart for both half-dose (0.5 ml: 50 µg SE36 + 500 µg aluminum + 500 µg K3) and full-dose (1.0 ml: 100 µg SE36 + 1000 µg aluminum + 1000 µg K3). A one-year follow-up was done to monitor changes in autoimmune markers and vaccine-induced antibody response. RESULTS: BK-SE36/CpG was well tolerated. Vaccination site reactions were similar to those observed with BK-SE36. During the trial and follow-up period, no subject had clinical evidence of autoimmune disease. The full-dose group had significantly higher titres than the half-dose group (Student's t-test, p = 0.002) at 21 days post-second vaccination. Antibody titres remained above baseline values during 12 months of follow-up. The vaccine induced antibody was mostly composed of IgG1 and IgM, and recognised epitopes close to the polyserine region located in the middle of SE36. CONCLUSIONS: BK-SE36/CpG has an acceptable safety profile. Use of CpG-ODN(K3) greatly enhanced immunogenicity in malaria naïve Japanese adults when compared to BK-SE36 alone. The utility of BK-SE36/CpG is currently under evaluation in a malaria endemic setting in West Africa. TRIAL REGISTRATION: JMACCT Clinical Trial Registry JMA-IIA00109.
引用
- Ezoe S, Palacpac NMQ, Tetsutani K, et al. First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3). Vaccine. 2020. PMID: 33012605. doi:10.1016/j.vaccine.2020.09.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。